GlassScriptPhysician profile
Oleksandra Los
NPI 1871158964
$17,868.33
in general payments reported to CMS, 2019-2025
22 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $12K · 2024: $4,256 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $10K · Travel and Lodging: $4,423 · Food and Beverage: $3,442 · Education: $3.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $10,000.00 |
| Travel and Lodging | $4,423.12 |
| Food and Beverage | $3,441.81 |
| Education | $3.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15,447.17 | 2023-2025 | Activa PC, Percept PC Brainsense, Intellis Adaptivestim |
| Boston Scientific Corporation | $774.59 | 2024 | Vercise |
| Acadia Pharmaceuticals INC | $476.02 | 2023-2024 | Nuplazid, Daybue |
| Abbvie INC. | $306.20 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $138.42 | 2023 | Rytary |
| Biogen, INC. | $121.89 | 2024 | |
| Abbott Laboratories | $116.48 | 2024 | Infinity |
| Ucb, INC. | $60.08 | 2023-2024 | Fintepla, Rystiggo |
| Ipsen Biopharmaceuticals, INC | $57.54 | 2024 | Dysport |
| Teva Pharmaceuticals USA, INC. | $50.51 | 2023-2024 | Austedo Xr |
| Genentech USA, INC. | $48.28 | 2023-2024 | Enspryng, Ocrevus |
| Neurocrine Biosciences, INC. | $47.48 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $43.68 | 2023-2024 | Hyqvia |
| Lilly USA, LLC | $23.79 | 2024 | Emgality |
| Eisai INC. | $23.01 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.79 | 2023 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $21.09 | 2024 | Rexulti |
| Acorda Therapeutics, INC | $20.20 | 2024 | Inbrija |
| Novartis Pharmaceuticals Corporation | $19.24 | 2024 | |
| Emd Serono, INC. | $18.89 | 2024 | |
| Csl Behring | $16.73 | 2023 | Hizentra |
| Kyowa Kirin, INC. | $14.25 | 2023 | Nourianz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oleksandra Los listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.